Nivolumab induced radiation recall pneumonitis after two years of radiotherapy

Abstract

Nivolumab, a first-in-class anti-programmed cell death-1 (anti-PD-1) antibody, has become the standard second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Nivolumab sometimes causes immune-related adverse events. Pneumonitis occurred in 3% of patients in the pivotal trial [1], but its nature had not been fully elucidated. Here, we present two cases of a unique pattern of nivolumab-related pneumonitis.